High Court Stays Mum On Teva MS Drug Patent Suit

Law360, New York (March 24, 2014, 7:18 PM EDT) -- The U.S. Supreme Court on Monday took no action for a second time in a patent case over Teva Pharmaceuticals USA Inc.'s lucrative multiple sclerosis drug Copaxone, as the clock ticks toward a possible May launch for planned generic versions of the drug.

Teva is appealing a July ruling by the Federal Circuit invalidating several patents covering the drug, which had worldwide sales of $4.3 billion in 2013, and clearing the way for generic versions. The high court was slated to discuss the case at its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.